Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic Leukemia

Launched by JANSSEN CILAG S.A.S. · Mar 1, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how a personalized physical activity program can improve the quality of life for people with chronic lymphocytic leukemia (CLL) who are starting treatment with a medication called ibrutinib. The researchers want to see if getting regular exercise can help participants feel better and improve their overall well-being. To measure this, they will use a questionnaire that asks about various aspects of health and daily life.

To join the study, participants need to be newly treated with ibrutinib for either initial or returning CLL and agree to follow the physical activity program. They should have access to a smartphone, tablet, or laptop, and the internet, as they will need to wear a connected watch to track their activity throughout the study. Unfortunately, individuals who are pregnant, unable to safely exercise, or currently participating in another clinical trial cannot participate. If you or a loved one are eligible, this study offers a chance to explore how physical activity might enhance daily life while undergoing treatment.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants newly treated with ibrutinib for first line or relapsed CLL (treatment is being initiated or has been initiated within the last 8 days as a maximum)
• • Participants agreed to follow the individual physical activity intervention (IPAI)
• • Participants using or having access to a compatible and appropriate electronic device such as smartphone, laptop or tablet
• • Participants with Internet access at home and email address
• • Participants agreed to wear a connected watch 24 hours a day for all the duration of the study
• Exclusion Criteria:
• • Pregnant participants or planning to become pregnant while enrolled in this study
• • Participants with inability or deemed unsafe to practice physical activity
• • Participants who have received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 90 days before the inclusion visit
• • Participants who are currently involved in an interventional study
• • Participants with probable difficulties in using the digital tool autonomously